MT2014-10C : Allogeneic Hematopoietic Stem Cell Transplant for Patients with High Risk Hemoglobinopathies and Other Red Cell Transfusion Dependent Disorders

Sex: All

Age Group: Up to 55 years old

Inclusion Criteria:

Diagnosis of Sickle Cell Disease, Thalassemia, Diamond Blackfan Anemia or other non-malignant hematologic disorders for which a stem cell transplant is indicated Acceptable stem cell source identified Performance status of ≥ 70% (Karnofsky),or ≥ 70 (Lansky play score) Creatinine <2.0 mg/dl for adults or glomerular filtration rate > 50 ml/min for children Bilirubin, Aspartate Aminotransferase, Alkaline phosphatase <5 times the upper limit of institutional normal Absence of decompensated congestive heart failure, or uncontrolled arrhythmia and left ventricular ejection fraction > 40%

Exclusion Criteria:

active, uncontrolled infection pregnant or breastfeeding HIV positive

Interventions:

Drug: Myeloablative Preparative Regimen, Drug: Reduced Intensity Preparative Regimen, Drug: Reduced Toxicity Ablative Regimen

Keywords:

Clinics and Surgery Center (CSC)

Study Contact: Holly Franceen - hfrancee@umn.edu

Principal Investigator: Ashish Gupta

Phase: N/A

IRB Number: 1407M52125

See this study on ClinicalTrials.gov

MT2014-10C : Allogeneic Hematopoietic Stem Cell Transplant for Patients with High Risk Hemoglobinopathies and Other Red Cell Transfusion Dependent Disorders

Email this study information to me

Contact the study team